HETEROARENE SCOPE

2-(4-Methylquinolin-2-yl)chroman-4-one (2a)
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), lepidine (66 µL, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 
2-(Quinolin-2-yl)chroman-4-one (2b)
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), quinoline (64.6 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K 2 S 2 O 8 (135 mg, 0.05 mmol, 1.0 equiv). The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), affording the coupled product (96 mg, 70% yield) as a light yellow oil. 
H NMR (500 MHz
,
2-(4-Bromoquinolin-2-yl)chroman-4-one (2d)
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4-bromoquinoline (103.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K 2 S 2 O 8 (135 mg, 0.05 mmol, 1.0 equiv).
The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), affording the coupled product (88 mg, 50% yield) as a semi-solid. The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc),
affording the coupled product (53.8 mg, 66% yield) as a pale yellow oil. 
2-(4-Chloro-8-(trifluoromethyl)quinolin-2-yl)chroman-4-one (2g)
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 4- 
2-(1-Chloroisoquinolin-3-yl)chroman-4-one (2h)
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 1-chloroisoquinoline (81.5 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K 2 S 2 O 8 (135 mg, 0.05 mmol, 1.0 equiv).
The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), affording the coupled product (46.4 mg, 30% yield) as a pale yellow oil. The title compound was purified by column chromatography (silica gel, 4:1 hexanes/EtOAc), affording the coupled product (88 mg, 50% yield) as a white solid (mp = 179-181 °C). 
2-(Quinoxalin-2-yl)chroman-4-one (2k)
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), quinoxaline (65.1 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate 
2-(3-Chloroquinoxalin-2-yl)chroman-4-one (2l)
The general procedure was followed with trifluoroborate (191 mg, 0.75 mmol, 1.5 equiv), 2-chloroquinoxaline (82 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K 2 S 2 O 8 (135 mg, 0.05 mmol, 1.0 equiv).
The title compound was purified by column chromatography (silica gel, 3:1 hexanes/EtOAc), affording the coupled product (77.5 mg, 50% yield) as a semi-solid. 
2-(4-(Trifluoromethyl)pyridin-2-yl)chroman-4-one (2n)
6-Bromo-2-(8-chloro-2-methylquinolin-4-yl)chroman-4-one (4d)
The general procedure was followed with trifluoroborate (249 mg, 0.75 mmol, 1.5 equiv), 2-methyl-8-chloroquinoline (89 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate (1.5 mg, 0.005 mmol, 0.01 equiv), and K 2 S 2 O 8 (135 mg, 0.05 mmol, 1.0 equiv).
The title compound was purified by column chromatography (silica gel, 5:1 hexanes/EtOAc), affording the coupled product (124.3 mg, 62% yield) as a semi-solid. 
FT-IR
6-Bromo-2-(quinoxalin-2-yl)chroman-4-one (4f)
The general procedure was followed with trifluoroborate (249 mg, 0.75 mmol, 1.5 equiv), quinoxaline (65.1 mg, 0.50 mmol, 1.0 equiv), 9-mesityl-10-methylacridinium tetrafluoroborate freshly distilled EtOH (20 mL) was added, and the mixture was stirred for 3 h at rt. Upon completion of the reaction, the EtOH was removed in vacuo, and the residue was dissolved in
FT-IR
GENERAL PROCEDURE FOR BETA BORYLATION
MeOH (20 mL) and cooled to 0 °C. Saturated KHF 2 (8 mL, 4.5 M) was added dropwise to the reaction, and the resulting mixture was allowed to warm to rt. After 30 min, the solution was concentrated in vacuo and placed on the lyophilizer overnight. A Soxhlet extraction of the solid was performed using i-PrOAc for 16 h, and the extract was concentrated. The resulting red solid was dissolved in acetone (~5 mL), and Et 2 O was added dropwise until precipitation was induced.
Additional Et 2 O (20 mL) was added, and the solid was filtered to afford a light orange powder (1.115 g, 84% yield). 
6-Bromo
